- TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status
- Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA)
Catalyst
Slingshot members are tracking this event:
Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tecentriq, Pd-l1, Atezolizumab
